Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

380 ARTÍCULOS , VIENDO DEL 331 AL 345

Almond, hazelnut and walnut, three nuts for neuroprotection in Alzheimer's disease: A neuropharmacological review of their bioactive constituents

Gorji N, Moeini R, Memariani Z.

Pharmacol Res. 2018 Mar;129:115-127. doi: 10.1016/j.phrs.2017.12.003. Epub 2017 Dec 5.

ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target

Davis W Jr, Tew KD.

Biochem Pharmacol. 2018 May;151:188-200. doi: 10.1016/j.bcp.2017.11.018. Epub 2017 Dec 6.

Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease

Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Joni Shah N, Langen KJ, Kutzsche J, Willbold D, Willuweit A.

Eur J Pharm Sci. 2018 Mar 1;114:93-102. doi: 10.1016/j.ejps.2017.12.005. Epub 2017 Dec 7.

Amylin in Alzheimer's disease: Pathological peptide or potential treatment?

Mietlicki-Baase EG.

Neuropharmacology. 2018 Jul 1;136(Pt B):287-297. doi: 10.1016/j.neuropharm.2017.12.016. Epub 2017 Dec 9.

Suvorexant for the treatment of insomnia in patients with Alzheimer's disease

Hamuro A, Honda M, Wakaura Y.

Aust N Z J Psychiatry. 2018 Feb;52(2):207-208. doi: 10.1177/0004867417747402. Epub 2017 Dec 14.

Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?

Becker RE, Kapogiannis D, Greig NH.

Alzheimers Dement. 2018 Apr;14(4):431-443. doi: 10.1016/j.jalz.2017.11.007. Epub 2017 Dec 12.

Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease

Sahoo AK, Dandapat J, Dash UC, Kanhar S.

J Ethnopharmacol. 2018 Apr 6;215:42-73. doi: 10.1016/j.jep.2017.12.015. Epub 2017 Dec 14.

Tramadol ameliorates behavioural, biochemical, mitochondrial and histological alterations in ICV-STZ-induced sporadic dementia of Alzheimer's type in rats

Dhull DK, Kumar A.

Inflammopharmacology. 2018 Aug;26(4):925-938. doi: 10.1007/s10787-017-0431-3. Epub 2017 Dec 16.

Cinnamon, a promising prospect towards Alzheimer's disease

Momtaz S, Hassani S, Khan F, Ziaee M, Abdollahi M.

Pharmacol Res. 2018 Apr;130:241-258. doi: 10.1016/j.phrs.2017.12.011. Epub 2017 Dec 16.

Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders

Augustin K, Khabbush A, Williams S, Eaton S, Orford M, Cross JH, Heales SJR, Walker MC, Williams RSB.

Lancet Neurol. 2018 Jan;17(1):84-93. doi: 10.1016/S1474-4422(17)30408-8. Epub 2017 Dec 16.

Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease

Kumar K, Kumar A, Keegan RM, Deshmukh R.

Biomed Pharmacother. 2018 Feb;98:297-307. doi: 10.1016/j.biopha.2017.12.053. Epub 2017 Dec 27.

Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease

Caraci F, Nicoletti F, Copani A.

Curr Opin Pharmacol. 2018 Feb;38:1-7. doi: 10.1016/j.coph.2017.12.001. Epub 2017 Dec 23.

An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer's disease

Marcelli S, Ficulle E, Piccolo L, Corbo M, Feligioni M.

Pharmacol Res. 2018 Apr;130:420-437. doi: 10.1016/j.phrs.2017.12.023. Epub 2017 Dec 26.

A review on the hybrids of hydroxycinnamic acid as multi-target-directed ligands against Alzheimer's disease

Zhang X, He X, Chen Q, Lu J, Rapposelli S, Pi R.

Bioorg Med Chem. 2018 Feb 1;26(3):543-550. doi: 10.1016/j.bmc.2017.12.042. Epub 2017 Dec 26.

Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5

Brody AH, Strittmatter SM.

Adv Pharmacol. 2018;82:293-323. doi: 10.1016/bs.apha.2017.09.007. Epub 2017 Oct 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias